EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 1, 2007, Pages 53-61

  Dassonville, Olivier ^a   Bozec, Alexandre ^a   Fischel, Jean Louis ^a   Milano, Gerard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

EGFR; Monoclonal antibodies; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CANERTINIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; VANDETANIB;

CANCER; CANCER CELL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; NONHUMAN; REVIEW; TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33847273041     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.12.008     Document Type: Review

References (105)

1. Tortora G., Caputo R., Damiano V., et al. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res 7 (2001) 4156-4163
2. Albanell J., Rojo F., and Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 28 (2001) 56-66
3. Chinnaiyan P., and Harari P.M. Clinical advancement of EGFR inhibitors in cancer therapy. Methods Mol Biol 327 (2006) 189-202
4. Cerea G., Ricotta R., Schiavetto I., et al. Cetuximab for treatment of metastatic colorectal cancer. Ann Oncol 17 Suppl 7 (2006) vii66-vii67
5. Saba N.F., Khuri F.R., and Shin D.M. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park) 20 (2006) 153-161 discussion 162, 166, 169 passim
6. Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 1 (2005) 221-234
7. Vincenzi B., Santini D., and Tonini G. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor. J Clin Oncol 24 (2006) 1957 author reply 1957-1958
8. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
9. Reck M., and Gatzemeier U. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. Respir Med 99 (2005) 298-307
10. Herbst R.S., and Erlotinib. (Tarceva): an update on the clinical trial program. Semin Oncol 30 (2003) 34-46
11. Sparano J.A., Gray R., Giantonio B., O'Dwyer P., Comis R.L., and The Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Evaluating antiangiogenesis agents in the clinic. Clin Cancer Res 10 (2004) 1206-1211
12. Siegel-Lakhai W.S., Beijnen J.H., and Schellens J.H. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10 (2005) 579-589
13. Buter J., and Giaccone G. EGFR inhibitors in lung cancer. Oncology (Williston Park) 19 (2005) 1707-1711 discussion 1711-1702, 1720-1703
14. Bianco R., Melisi D., Ciardiello F., and Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42 (2006) 290-294
15. Fan Z., Lu Y., Wu X., and Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269 (1994) 27595-27602
16. Prewett M., Rockwell P., Rockwell R.F., et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19 (1996) 419-427
17. Noonberg S.B., and Benz C.C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59 (2000) 753-767
18. Denny W.A. Irreversible inhibitors of the erbB family of protein tyrosine kinases. Pharmacol Ther 93 (2002) 253-261
19. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 (2001) 32S-40S
20. Citri A., Alroy I., Lavi S., et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 21 (2002) 2407-2417
21. Gilmore A.P., Valentijn A.J., Wang P., et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 277 (2002) 27643-27650
22. Liu B., Fang M., Lu Y., Mendelsohn J., and Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20 (2001) 1913-1922
23. Kiyota A., Shintani S., Mihara M., et al. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 63 (2002) 92-98
24. Fan Z., Shang B.Y., Lu Y., Chou J.L., and Mendelsohn J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 3 (1997) 1943-1948
25. Huang S.M., Li J., Armstrong E.A., and Harari P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62 (2002) 4300-4306
26. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
27. Ciardiello F., Bianco R., Damiano V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6 (2000) 3739-3747
28. Liu B., Fang M., Schmidt M., Lu Y., Mendelsohn J., and Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 82 (2000) 1991-1999
29. Liu B., and Fan Z. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. Oncogene 20 (2001) 3726-3734
30. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
31. Hirata A., Ogawa S., Kometani T., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62 (2002) 2554-2560
32. Bozec A., Formento P., Ciccolini J., et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 4 (2005) 1962-1971
33. Bandyopadhyay D., Mandal M., Adam L., Mendelsohn J., and Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273 (1998) 1568-1573
34. Yacoub A., McKinstry R., Hinman D., Chung T., Dent P., and Hagan M.P. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159 (2003) 439-452
35. Normanno N., Tortora G., De Luca A., et al. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep 6 (1999) 1105-1109
36. Overholser J.P., Prewett M.C., Hooper A.T., Waksal H.W., and Hicklin D.J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89 (2000) 74-82
37. Bos M., Mendelsohn J., Kim Y.M., Albanell J., Fry D.W., and Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 3 (1997) 2099-2106
38. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (1995) 1311-1318
39. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6 (2000) 2053-2063
40. Magne N., Fischel J.L., Dubreuil A., et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86 (2002) 819-827
41. Milano G. Pharmacological skills for targeting EGFR and VEGF. Bull Cancer 92 (2005) S17-S20
42. Lammerts van Bueren J.J., Bleeker W.K., Bogh H.O., et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 66 (2006) 7630-7638
43. Carter P. Improving the efficacity of antibody-based cancer therapies. Nat Rev Cancer 2 (2001) 118-129
44. Gieseg M.A., de Bock C., Ferguson L.R., and Denny W.A. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 12 (2001) 683-690
45. Fan Z., Baselga J., Masui H., and Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53 (1993) 4637-4642
46. Tortora G., Caputo R., Pomatico G., et al. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res 5 (1999) 875-881
47. Bruns C.J., Harbison M.T., Davis D.W., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6 (2000) 1936-1948
48. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., and Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8 (2002) 994-1003
49. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
50. Folprecht G., Lutz M.P., Schoffski P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17 (2006) 450-456
51. Martinez-Lacaci I., Kannan S., De Santis M., et al. RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells. Int J Cancer 88 (2000) 44-52
52. Zhang P., Wang Y.Z., Kagan E., and Bonner J.C. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J Biol Chem 275 (2000) 22479-22486
53. Raben D., Bianco C., Helfrich B., Weng E., Ciardiello F., and Harari P. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment. Expert Rev Anticancer Ther 2 (2002) 461-471
54. Williams K.J., Telfer B.A., Stratford I.J., and Wedge S.R. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86 (2002) 1157-1161
55. Bozec A., Fischel J.L., and Milano G. Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol 18 (2006) 330-334
56. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
57. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
58. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
59. Magne N., Fischel J.L., Dubreuil A., et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 86 (2002) 1518-1523
60. Solbach C., Roller M., Ahr A., et al. Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int J Cancer 101 (2002) 390-394
61. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286
62. Penault-Llorca F., Bibeau F., Arnould L., Bralet M.P., Rochaix P., and Sabourin J.C. EGFR expression in colorectal cancer and role in tumorigenesis. Bull Cancer 92 (2005) S5-S11
63. Moscatello D.K., Holgado-Madruga M., Godwin A.K., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55 (1995) 5536-5539
64. Moscatello D.K., Montgomery R.B., Sundareshan P., McDanel H., Wong M.Y., and Wong A.J. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13 (1996) 85-96
65. Cheng S.Y., Huang H.J., Nagane M., et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93 (1996) 8502-8507
66. Aoji K., Nishioka S., Nishikawa K., and Koike S. Mandibular reconstruction using a vascularized osteocutaneous scapular flap. Nippon Jibiinkoka Gakkai Kaiho 97 (1994) 41-50
67. Wikstrand C.J., Hale L.P., Batra S.K., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55 (1995) 3140-3148
68. Huang H.S., Nagane M., Klingbeil C.K., et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272 (1997) 2927-2935
69. Wikstrand C.J., McLendon R.E., Friedman A.H., and Bigner D.D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57 (1997) 4130-4140
70. Sugawa N., Ekstrand A.J., James C.D., and Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87 (1990) 8602-8606
71. Heimberger A.B., Suki D., Yang D., Shi W., and Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3 (2005) 38
72. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
73. Matsumoto K., Akagi K., Abekura M., Ohkawa M., Tasaki O., and Tomishima T. Cosmetic and functional reconstruction achieved using a split myofascial bone flap for pterional craniotomy. Technical note. J Neurosurg 94 (2001) 667-670
74. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
75. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
76. Marchetti A., Martella C., Felicioni L., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
77. Sakurada A., Shepherd F.A., and Tsao M.S. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer 7 Suppl 4 (2006) S138-S144
78. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
79. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 2556-2568
80. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
81. Janne P.A., Engelman J.A., and Johnson B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23 (2005) 3227-3234
82. Han S.W., Kim T.Y., Hwang P.G., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
83. Shimizu J., Horio Y., and Mitsudomi T. Molecular targeted therapy-non-small-cell lung cancer and gefitinib. Gan To Kagaku Ryoho 32 (2005) 1879-1885
84. Mukohara T., Engelman J.A., Hanna N.H., et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97 (2005) 1185-1194
85. Chakravarti A., Chakladar A., Delaney M.A., Latham D.E., and Loeffler J.S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62 (2002) 4307-4315
86. Bianco R., Shin I., Ritter C.A., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22 (2003) 2812-2822
87. Christensen J.G., Schreck R.E., Chan E., et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 7 (2001) 4230-4238
88. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
89. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61 (2001) 5090-5101
90. Bozec A, Formento P, Fischel JL, Hofman P, Etienne MC, Milano G. Combined effect of EGFR targeting with antiangiogenesis and irradiation. In AACR, edition 2006.
91. McCarty M.F., Wey J., Stoeltzing O., et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3 (2004) 1041-1048
92. Heymach J.V., Nilsson M., Blumenschein G., Papadimitrakopoulou V., and Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12 (2006) 4441s-4445s
93. Seiden M.V., Burris H.A., Matulonis U., et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol (2006)
94. Nelson M.H., and Dolder C.R. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40 (2006) 261-269
95. Jorm A.F., Anstey K.J., Christensen H., et al. MRI hyperintensities and depressive symptoms in a community sample of individuals 60-64 years old. Am J Psychiatry 162 (2005) 699-705
96. Gibson T.B., Ranganathan A., and Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6 (2006) 29-31
97. Heymach J.V. ZD6474-clinical experience to date. Br J Cancer 92 Suppl 1 (2005) S14-S20
98. Konecny G.E., Pegram M.D., Venkatesan N., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 (2006) 1630-1639
99. Arteaga C.L. Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?. Clin Cancer Res 9 (2003) 1231-1232
100. Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 90 (2004) 2250-2255
101. Ranson M., and Sliwkowski M.X. Perspectives on anti-HER monoclonal antibodies. Oncology 63 Suppl 1 (2002) 17-24
102. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 3234-3243
103. Saif M.W., and Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 6 (2006) 118-124
104. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
105. Hamilton M., Wolf J., Rusk J., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 1 (2006) 2166-2171